It’s unnecessary to fast before a complete cholesterol test, according to new research, especially if the sole intention of that test is to determine a patient’s risk of future cardiovascular events.

Millennials in their mid-thirties are less healthy than Generation Xers were at the same age, a recent analysis by Blue Cross Blue Shield found—a gap driven largely by poorer mental, cardiovascular and endocrine health outcomes in the younger generation.

Research backed by Brazil’s Sao Paulo Research Foundation found overweight teenagers face the same increased risk of developing heart disorders as their obese counterparts—a conclusion that contradicts the popular idea that the heavier a person is, the higher their CV risk.

Type 2 diabetes patients who undergo gastric bypass surgery as teenagers are more likely to achieve remission of their diabetes and hypertension in adulthood than adults who attempt the same procedure years later, according to a study funded by the National Institutes of Health.

More than one-third of statin patients still fail to reach healthy LDL-cholesterol levels a year and a half after initiating treatment, leaving them vulnerable to adverse CV events and thousands of dollars in medical bills, according to a report in the Journal of Managed Care & Specialty Pharmacy.

Drugmaker Zydus Cadila on May 13 announced it had received final approval from the FDA to market chlorthalidone tablets, the generic equivalent of Pfizer’s now-discontinued hypertension drug Thalitone.

The FDA has tied sodium-glucose cotransporter-2 inhibitors to 55 cases of a life-threatening form of gangrene in the past six years, according to a May 7 report in the Annals of Internal Medicine.

Diabetic ketoacidosis is more prevalent in the U.S. than it is in Canada, according to a joint analysis from Harvard Medical School, the Cambridge Health Alliance, City University of New York and the University of Manitoba.